finanzwire.de

Search

MOLOGEN AG (FRA:MGN) DGAP-Adhoc: MOLOGEN AG: U.S. patent for lead product MGN1703 in combination with chemotherapy announced

Transparency directive : regulatory news

02/09/2015 21:13

12/11/2018 10:50
08/11/2018 16:45
08/11/2018 07:06
05/11/2018 08:36
26/10/2018 19:01
22/10/2018 09:24
08/10/2018 17:29
04/10/2018 11:08
27/09/2018 07:36
26/09/2018 16:52
MOLOGEN AG / Key word(s): Patent 02.09.2015 21:13 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Ad-hoc notification according to § 15 WpHG MOLOGEN AG: U.S. patent for lead product MGN1703 in combination with chemotherapy announced Berlin, September 2, 2015 - MOLOGEN AG announces that the United States Patent and Trademark Office (PTO) has declared that it will grant a patent (Notice of Allowance) for the combined use of the lead product, immunotherapy MGN1703, with a chemotherapeutic agent. MGN1703 is currently being tested in a phase III IMPALA pivotal study, both as a monotherapy and in combination with chemotherapy. The patent will be granted for the USA and would, in the event of market approval there, cover the dosing regimen for MGN1703 in combination with chemotherapy. In addition, the patent will last probably several years longer than the initial patent for MGN1703 (substance patent) and would therefore permit a longer exclusive commercialization than the initial patent. Contact Claudia Nickolaus Head of Investor Relations & Corporate Communications Tel: +49 - 30 - 84 17 88 - 38 Fax: +49 - 30 - 84 17 88 - 50 investor@mologen.com Note about risk for future predictions Certain information in this report contains forward-looking statements or the corresponding statements with negation or versions deviating from this or comparable terminology. These are described as forward-looking statements. In addition, all of the information given here that refers to planned or future results of business areas, key financial figures, developments of the financial situation or other financial figures or statistical data, is to be understood as such forward-looking statements. The company points out to investors that they should not rely on these forward-looking statements as predictions about actual future events. The company is not obligated and refuses to accept any liability for the forward-looking statements and has no obligation to update such statements in order to accurately reflect the current situation. 02.09.2015 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: MOLOGEN AG Fabeckstraße 30 14195 Berlin Germany Phone: 030 / 841788-0 Fax: 030 / 841788-50 E-mail: presse@mologen.com Internet: www.mologen.com ISIN: DE0006637200 WKN: 663720 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart End of Announcement DGAP News-Service ---------------------------------------------------------------------------